Trial Profile
The effects of the proliferator-activated receptor gamma (PPARy) peroxisome agonist rosiglitazone on airway hyperreactivity.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Sep 2011
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Asthma
- Focus Pharmacodynamics
- 01 Sep 2011 Actual initiation date (Dec 2008) added as reported by ClinicalTrials.gov.
- 01 Sep 2011 Primary endpoint identified as Methacholine provocation concentration as reported by ClinicalTrials.gov.
- 31 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.